Moderna (MRNA) beats estimates in Q1 2024, targets RSV vaccine launch in fall
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Moderna (MRNA) PT Raised to $135 at RBC Capital
May 3, 2024 6:45 AM EDTRBC Capital analyst Luca Issi raised the price target on Moderna (NASDAQ: MRNA) to $135.00 (from $125.00) while maintaining a Outperform rating.
The analyst comments "Bottom line was a beat primarily on lower OpEx. Guide was reiterated ($4b revenue and $8.1b costs), and we like... More
Moderna (MRNA) PT Raised to $95 at Morgan Stanley
May 2, 2024 4:14 PM EDTMorgan Stanley analyst Matthew Harrison raised the price target on Moderna (NASDAQ: MRNA) to $95.00 (from $89.00) while maintaining a Equalweight rating.
The analyst comments "Generally in line quarter, looking ahead the next catalysts for the stock are RSV vaccine PDUFA date May 12 (followed... More
Moderna (MRNA) Tops Q1 EPS by 48c
May 2, 2024 6:35 AM EDTModerna (NASDAQ: MRNA) reported Q1 EPS of ($3.07), $0.48 better than the analyst estimate of ($3.55). Revenue for the quarter came in at $167 billion versus the consensus estimate of $94.28 million.
For earnings history and earnings-related data on Moderna (MRNA) click here.
... More